Last reviewed · How we verify
NCT06118346
A Female-Specific CBT Group for Veteran Women With Alcohol Use Disorder in VA Primary Care Settings
NA trial testing Female-Specific Cognitive Behavioral Therapy (FS-CBT) in Alcohol Use Disorder in 162 participants. Currently enrolling.
30 July 2026
Quick facts
| Lead sponsor | University of Massachusetts, Worcester |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 162 |
| Start date | 24 February 2023 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Female-Specific Cognitive Behavioral Therapy (FS-CBT)
- Usual Care
Conditions studied
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
- Risky Health Behavior — all drugs for Risky Health Behavior →
Sponsor
University of Massachusetts, Worcester
Who can join
18 and older, female only, with Alcohol Use Disorder or Risky Health Behavior. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate a Female-Specific Cognitive Behavioral Therapy (CBT) Group as treatment for Alcohol Use Disorder among Veteran women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06118346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcohol Use Disorder
Currently open trials in the same condition.
- NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
- NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
- NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
Other University of Massachusetts, Worcester trials
Trials by the same sponsor.
- NCT07431528 — Dementia and Storytelling in Vietnam · NA · not yet recruiting
- NCT07060664 — Study on Outcomes of Proximal Humerus Fractures · NA · not yet recruiting
- NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT06100809 — Does Fatigue Coaching Improve Functioning and Fatigue in Resident Night Shifts · NA · not yet recruiting
- NCT06246539 — Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06118346 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Worcester
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06118346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing